Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Monotherapy in Advanced or Metastatic Solid Tumors
NCT04911907Phase 2Completed
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Jan 2021
- Primary completion
- May 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in solid tumor, head and neck squamous cell carcinoma (HNSCC), esophageal cancer, gastric cancer (GC), pancreatic cancer (PC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started Jan 2021; status: completed.
02
Drugs
utidelone
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)esophageal cancergastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04911907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911907.